Friday, Nov 20, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

Phase 3 SURMOUNT-1 enrolled 2,539 adults without diabetes under the stated BMI criteria.

The Claim

The Phase 3 SURMOUNT-1 trial enrolled 2,539 adults without diabetes who had a body-mass index of at least 30, or at least 27 with at least one weight-related complication.

The Short Version

The enrollment total and eligibility criteria are accurately stated. The primary trial publication, FDA review and official registry confirm that Phase 3 SURMOUNT-1 enrolled 2,539 adults without diabetes, with a BMI of at least 30, or at least 27 with at least one weight-related complication. Additional eligibility requirements do not change the accuracy of this summary.

Caveats

  • The claim summarizes eligibility rather than listing every requirement; participants also needed a prior unsuccessful dietary effort.
  • Protocol enrollment targets should not be confused with the final actual enrollment of 2,539.
  • Several secondary summaries reproduce the primary publication and are not independent confirmations.

The Receipts

  1. 217806Orig1s000

    accessdata.fda.gov

  2. Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

    nejm.org

  3. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

    pmc.ncbi.nlm.nih.gov

  4. Tirzepatide Once Weekly for the Treatment of Obesity - PubMed

    pubmed.ncbi.nlm.nih.gov

  5. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

    clinicaltrials.gov

  6. Tirzepatide: A New Anti-Obesity Medication

    doi.org

  7. Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects

    doi.org

  8. Tirzepatide Once Weekly for the Treatment of Obesity - SURMOUNT-1

    acc.org

  9. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

    doi.org

  10. Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks | AFP

    aafp.org

+ 18 more sources — see the full list on Lenz

Filed Under

SURMOUNT-1

More Fact Checks